Quick Answer
ANI PHARMACEUTICALS INC reported Revenue From Contract With Customer Excluding Assessed Tax of $883.37 million for the year ending 2025.
- ANI PHARMACEUTICALS INC showed an increase of +43.8% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from ANI PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $52.89 million | Q2 2019: $54.36 million | Q3 2019: $51.34 million | Q4 2019: $47.97 million | Q1 2020: $49.77 million | Q2 2020: $48.47 million | Q3 2020: $52.98 million | Q4 2020: $57.25 million | Q1 2021: $54.52 million | Q2 2021: $48.63 million | Q3 2021: $52.06 million | Q1 2022: $64.48 million | Q2 2022: $73.86 million | Q3 2022: $83.82 million | Q1 2023: $106.79 million | Q2 2023: $116.55 million | Q3 2023: $131.83 million | Q1 2024: $137.43 million | Q2 2024: $138.04 million | Q3 2024: $148.33 million | Q1 2025: $197.12 million | Q2 2025: $211.37 million | Q3 2025: $227.81 million.
- Over the full 8 years of available data (2018 to 2025), ANI PHARMACEUTICALS INC's Revenue From Contract With Customer Excluding Assessed Tax has grown by 338.2%.
- Historical annual values: Fiscal year 2025: $883.37 million | Fiscal year 2024: $614.38 million | Fiscal year 2023: $486.82 million | Fiscal year 2022: $316.39 million | Fiscal year 2021: $216.14 million | Fiscal year 2020: $208.48 million | Fiscal year 2019: $206.55 million | Fiscal year 2018: $201.58 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: